AEterna Zentaris Inc. (AEZS)

[Investwisely123]

The deal between Novo Nordisk and Strongbridge Biopharma on October 31, 2018 changed everything for. AEZS for the better. According to the deal, Novo Nordisk paid $181.7 million dollars upfront to Strongbridge (SBBP) for Macrilen rights only in USA and Canada, not including Royalties Novo Nordisk must pay to both AEZS and SBBP for Macrilen sales in the USA and Canada. Macrilen value is now through the roof. AEZS still has FULL worldwide rights to Macrilen outside the USA and Canada. Imagine what Novo Nordisk or other big pharma will pay AEZS for Macrilen rights worldwide outside of the USA and Canada such as in Europe, Asia, etc. Market cap for Aezs is currently under $50 million dollars. Lots of room for the share price and market cap of Aezs to grow. Aezs share price in my opinion could easily reach $9-$11 on a buyout within the next two to three months. https://globenewswire.com/news-release/2018/10/31/1640246/0/en/Strongbridge-Biopharma-plc-Enters-into-Agreement-for-Novo-Nordisk-to-Acquire-the-U-S-and-Canadian-Rights-to-MACRILEN-macimorelin.html